2. Search Result
Search Result
No matches for "

54752

" within the MedChemExpress (MCE) catalog. Here are the results you might be looking for.

9

Inhibitors & Agonists

1

Peptides

1

Inhibitory Antibodies

10

Antibodies

4

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0792
    CZC-54252

    		LRRK2 Neurological Disease
    CZC-54252 is a potent and selective LRRK2 inhibitor with IC50s of 1.28 nM and 1.85 nM for wild-type and G2019S LRRK2, respectively. CZC-54252 attenuates G2019S LRRK2-induced human neuronal injury with an EC50 of ~1 nM. CZC-54252 has a neuroprotective activity .
    CZC-54252
  • HY-P990690
    Volrustomig

    MEDI-5752

    		 PD-1/PD-L1 CTLA-4 Cancer
    Volrustomig (MEDI-5752) is a human IgG1 κ monoclonal antibody targeting CTLA4/PD1. The isotype control for Volrustomig is Human IgG1 kappa, Isotype Control (HY-P99001). Volrustomig anchors to the surface of T cells by binding PD-1, induces PD-1 internalization and degradation, and preferentially inhibits CTLA-4 on activated PD-1 + T cells. Volrustomig binds to tumor-infiltrating lymphocytes and a subset of PD-1 + B cells, enhances T cell function and IFNγ secretion. Volrustomig reduces the activation of non-tumor-infiltrating lymphocytes and exhibits manageable toxicity. Volrustomig can be used in research on various cancers, such as non-small cell lung cancer, gastric cancer, hepatobiliary cancer, and cervical cancer .
    Volrustomig
  • HY-P10300
    CXCL8 (54-72)

    IL-8 (54-72)

    		 CXCR Inflammation/Immunology
    CXCL8 (54-72) is a C-terminal peptide based on the chemokine CXCL8. CXCL8 (54-72) has an interaction between a long and highly positively charged C-terminal region and a negative charge on the GAG that binds to the GAG. CXCL8 (54-72) can inhibit the adhesion and migration of neutrophils and adhesion of endothelial cells. CXCL8 (54-72) can be used to study chemokines in inflammatory response .
    CXCL8 (54-72)
  • HY-B0792A
    CZC-54252 hydrochloride

    		LRRK2 Neurological Disease
    CZC-54252 hydrochloride is a potent and selective LRRK2 inhibitor with IC50s of 1.28 nM and 1.85 nM for wild-type and G2019S LRRK2, respectively. G2019S LRRK2-induced human neuronal injury is attenuated by CZC-54252 hydrochloride with an EC50 of ~1 nM.CZC-54252 hydrochloride has a neuroprotective activity .
    CZC-54252 hydrochloride
  • HY-R01365
    hsa-miR-4752 mimic

    		MicroRNA Cancer
    hsa-miR-4752 mimics are small, chemically synthesized double-stranded RNAs that mimic endogenous miRNAs and enable miRNA functional analysis by up-regulation of miRNA activity.
    hsa-miR-4752 mimic
    hsa-miR-4752 mimic
  • HY-175445
    GNE-5472

    		PROTACs Estrogen Receptor/ERR IAP NF-κB TNF Receptor Apoptosis Cancer
    GNE-5472 is a potent bifunctional ERα PRRTAC degrader, with its E3 ligand being a pan-IAP antagonist. GNE-5472 antagonizes cIAP1/2, activating the non-classical NF-κB pathway, resulting in a significant upregulation of TNFα expression. GNE-5472 inhibits the proliferation of breast cancer cells and induces cell apoptosis. GNE-5472 can be used for the study of breast cancer .
    GNE-5472
  • HY-RI01365
    hsa-miR-4752 inhibitor

    		MicroRNA Cancer
    hsa-miR-4752 inhibitors are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA inhibitors have full-length nucleotide 2'-methoxy modification. The miRNA inhibitors strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning.
    hsa-miR-4752 inhibitor
    hsa-miR-4752 inhibitor
  • HY-R01365A
    hsa-miR-4752 agomir

    		MicroRNA Cancer
    hsa-miR-4752 agomirs are chemically-modified double-strand miRNA mimics with modified mature miRNA strand: 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 3' end cholesterol group, and full-length nucleotide 2'-methoxy modification. They are designed to mimic endogenous miRNAs and recommended for miRNA functional studies. Compared with miRNA mimics, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
    hsa-miR-4752 agomir
    hsa-miR-4752 agomir
  • HY-RI01365A
    hsa-miR-4752 antagomir

    		MicroRNA Cancer
    hsa-miR-4752 antagomirs are chemically-modified oligonucleotides that hybridize with mature miRNAs. The miRNA antagomirs have 2 phosphorothioates at the 5' end, 4 phosphorothioates at the 3' end, 1 cholesterol group at the 3' end, and full-length nucleotide 2'-methoxy modification. The miRNA antagomirs strongly compete with mature miRNAs to prevent the complementary pairing of miRNAs and their target genes, thereby inhibiting miRNAs from functioning. Stability of miRNA antagomirs appears to be significantly higher than miRNA inhibitors, they exhibits enhanced cellular uptake, stability and regulatory activity in vivo.
    hsa-miR-4752 antagomir
    hsa-miR-4752 antagomir

Inquiry Online

Submit your filled information, we will contact you soon.

Salutation: * Country or Region:
* Applicant Name: * Organization Name:
* Department:    
* Email Address: * Product Name:
Cat. No.: * Requested quantity:
* Phone Number:    
Remarks:

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: